Login / Signup

Beta-Blocker Interruption or Continuation after Myocardial Infarction.

Johanne SilvainGuillaume CaylaEmile FerrariGrégoire RangeEtienne PuymiratNicolas DelarchePaul GuedeneyThomas CuissetFabrice IvanesThibault LhermusierThibault PetroniGilles LemesleFrançois BresolesJean-Noël LabequeThibaut PommierJean-Guillaume DillingerFlorence LeclercqFranck BoccaraPascal LimTimothée Besseyre des HortsThierry FourmeFrançois JourdaAlain FurberBenoit LattucaNassim RedjimiChristophe ThuairePierre DeharoNiki ProcopiRaphaelle DumaineMichel SlamaLaurent PayotMohamad El KastyKarim AachaAbdourahmane DialloEric VicautGilles Montalescotnull null
Published in: The New England journal of medicine (2024)
In patients with a history of myocardial infarction, interruption of long-term beta-blocker treatment was not found to be noninferior to a strategy of beta-blocker continuation. (Funded by the French Ministry of Health and ACTION Study Group; ABYSS ClinicalTrials.gov number, NCT03498066; EudraCT number, 2017-003903-23.).
Keyphrases
  • angiotensin converting enzyme
  • healthcare
  • public health
  • heart failure
  • mental health
  • left ventricular
  • health information
  • risk assessment
  • social media